CALGB 50604: Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma

Study Status

Open to Enrollment

Study Description

This research study is being done in order to improve treatment outcomes in untreated patients diagnosed with early stage Hodgkin lymphoma.

A PET scan is an imaging technique that can detect the possibility of significant remaining active cancer. The purpose of this study is to find out if we can determine the type of chemotherapy that you may need for your Hodgkin lymphoma and whether or not you will need radiation therapy in addition to chemotherapy, based on your response during treatment as seen on PET scan images.

The first chemotherapy treatment in this study consists of a combination of four drugs approved by the Food and Drug Administration (FDA): doxorubicin, bleomycin, vinblastine, and dacarbazine. This regimen (called ABVD), either alone or combined with radiation therapy, has been found to be effective in treating patients with Hodgkin lymphoma.

PET scans will be performed during the course of your therapy to help evaluate the effectiveness of the chemotherapy treatment. We will evaluate the usefulness of these PET scans to determine if a change in chemotherapy and addition of radiation therapy may improve your chances of responding well to treatment.

If the PET scan is negative (there is no detectable remaining cancer), you will continue with ABVD chemotherapy without radiation therapy. If the PET is positive (there is detectable remaining cancer), your chemotherapy will be changed to a stronger regimen and you will receive radiation therapy in addition to chemotherapy.

You will be on study treatment for at least 5 ½ to 6 months. You will be asked to return to the clinic for follow-up:

  • every 3 months for the first year
  • every 4 months for the second and third years
  • every 6 months for the fourth and fifth years
  • and then once a year for a maximum of 10 years from the time you enter the study

Follow the Weill Cornell Lymphoma Program online:

Blog: cornell-lymphoma.com/blog

Facebook: facebook.com/lymphomaprogram

Twitter: twitter.com/lymphomaprogram

Disease Status and/or Stage

Hodgkin Lymphoma, Stage IA, IB, IIA or IIB

Sponsor

CALGB

Key Eligibility

  • Men and women age 18 to 60
  • Hodgkin lymphoma, Stage 1A, 1B, IIA, or IIB
  • May have had one cycle only of ABVD treatment prior to enrolling in the study; no other prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma is allowed
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Rebecca Elstrom, MD

Contact

Protocol ID

CALGB 50604

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page